Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First in Human Trial of TLC-ART 101 in Healthy Adults
NCT05850728Phase 1Completed
- Sponsor
- University of Washington
- Start
- Apr 2023
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TLC-ART 101 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by University of Washington. Primary endpoints: Peak TLC-101 Drug Substance Concentrations in Plasma at 64 days, Time to Maximum TLC-101 Concentration of Drug Substances in Plasma at 64 days and 3 more. Started Apr 2023; status: completed.
02
Drugs
TLC-ART 101
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05850728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850728.